Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors
{{output}}
The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resistance. In the September issue of Science, Lv et al.1 demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resi... ...
